keyword
MENU ▼
Read by QxMD icon Read
search

melanoma prognosis

keyword
https://www.readbyqxmd.com/read/28440443/microrna-expression-in-esophageal-squamous-cell-carcinoma-novel-diagnostic-and-prognostic-biomarkers
#1
Yan Wang, Jinnan Zhang, Wei Zhao, Donglin Wang, Wenduan Ma, Shengtao Shang, Chao Feng, Haixin Yu
The aim of the present study was to identify more effective molecular diagnostic biomarkers for esophageal squamous cell carcinoma (ESCC). The non‑coding RNA profile GSE43732, generated from 238 paired frozen tissues from 119 patients, was analyzed. Raw data were preprocessed and the differentially expressed miRNAs were screened by limma package with log2 fold change >2. Prognosis‑associated miRNAs were identified using receiver operating characteristic (ROC) and Kaplan-Meier (KM) curve analysis. miRNAs with an area under the ROC curve of ≥0...
April 13, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28435677/control-of-immune-cell-entry-through-the-tumour-vasculature-a-missing-link-in-optimising-melanoma-immunotherapy
#2
REVIEW
Lih Yin Tan, Carmela Martini, Zvi G Fridlender, Claudine S Bonder, Michael P Brown, Lisa M Ebert
Metastatic melanoma remains a fatal disease to many worldwide, even after the breakthrough introduction of targeted therapies such as BRAF inhibitors and immune checkpoint blockade therapies such as CTLA-4 and PD-1 inhibitors. With advances in our understanding of this disease, as well as the increasing data gathered from patient studies, the significance of the host immune response to cancer progression and response to treatment is becoming clear. More specifically, the presence of intratumoral CD8(+) cytotoxic T-cells correlates with better prognosis whereas the accumulation of monocytes/macrophages and neutrophils in the tumour is often associated with worse prognosis...
March 2017: Clinical & Translational Immunology
https://www.readbyqxmd.com/read/28435391/programmed-cell-death-1-checkpoint-inhibitors-in-the-treatment-of-patients-with-advanced-melanoma
#3
REVIEW
Jacek Mackiewicz, Andrzej Mackiewicz
The treatment landscape of advanced melanoma has changed significantly following the discovery and marketing authorisation of immune checkpoints inhibitors. Ipilimumab (anti-CTLA-4) was the first one to be approved, and it. demonstrated long-term survival in about 20% of patients. Subsequently, anti-programmed cell death-1 (a-PD-1) antibodies (pembrolizuamb, nivolumab), inhibitors of PD-1/programmed cell death-1 ligand (PD1-L) synapse, showed higher clinical efficacy with lower toxicity comparing to ipilimumab...
2017: Contemporary Oncology Współczesna Onkologia
https://www.readbyqxmd.com/read/28432682/prognostics-factors-and-survival-in-acral-lentiginous-melanoma
#4
M M Asgari, L Shen, M M Sokil, I Yeh, E Jorgenson
BACKGROUND: Acral lentiginous melanoma is a rare melanoma subtype that disproportionately afflicts people of color. Acral lentiginous melanomas have a worse prognosis than other melanomas subtypes, which has been attributed to aggressive biological behavior, more advanced stage at presentation and possible disparities in access to healthcare. OBJECTIVES: Using comprehensive patient data and long-term follow-up information in a well-characterized cohort, to examine how patient, tumor, and clinical management variables impact overall and melanoma-specific survival...
April 22, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28432169/primary-malignant-melanoma-of-the-cervix-a-rare-disease
#5
Ivo Julião, Sonia Dias Carvalho, Vanda Patricio, Ana Raimundo
Malignant melanoma (MM) arising primarily in the cervix is exceedingly rare and has a poor prognosis. We report the case of a primary MM of the cervix in a 64-year-old woman with vaginal bleeding. She presented with a cervical amelanotic lesion which on biopsy rendered the diagnosis of MM. The patient was staged as International Federation of Gynecology and Obstetrics IIB and underwent Wertheim-Meigshysterectomy followed by brachytherapy. One year later, she was diagnosed with a large pelvic relapse for which surgery was performed...
April 21, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28430756/does-pregnancy-influence-melanoma-prognosis-a-meta-analysis
#6
Athanassios Kyrgidis, Aimilios Lallas, Elvira Moscarella, Caterina Longo, Roberto Alfano, Giuseppe Argenziano
The literature has not been able to conclude whether pregnancy influences the prognosis of melanoma. The aim of this study was to explore the prognosis of melanoma diagnosed during pregnancy or post partum [pregnancy-associated melanoma (PAM)] compared with melanoma in female patients who were not pregnant. We systematically searched for studies of female patients with melanoma that reported outcomes related to survival. Fifteen eligible studies were found. Overall, PAM was associated with a 17% higher mortality compared with melanoma diagnosed in female patients who were not pregnant (hazard ratio=1...
April 20, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28430130/timp1-promotes-cell-survival-by-activating-the-pdk1-signaling-pathway-in-melanoma
#7
Mariana Toricelli, Fabiana H M Melo, Aline Hunger, Daniela Zanatta, Bryan E Strauss, Miriam G Jasiulionis
High TIMP1 expression is associated with poor prognosis in melanoma, where it can bind to CD63 and β1 integrin, inducing PI3-kinase pathway and cell survival. Phosphatidylinositol (3,4,5)-trisphosphate (PIP3), generated under phosphatidylinositol-3-kinase (PI3K) activation, enables the recruitment and activation of protein kinase B (PKB/AKT) and phosphoinositide-dependent kinase 1 (PDK1) at the membrane, resulting in the phosphorylation of a host of other proteins. Using a melanoma progression model, we evaluated the impact of Timp1 and AKT silencing, as well as PI3K, PDK1, and protein kinase C (PKC) inhibitors on aggressiveness characteristics...
April 21, 2017: Cancers
https://www.readbyqxmd.com/read/28428125/ovarian-metastasis-of-a-malignant-melanoma-a-case-report
#8
A Mendel, J J Terzibachian, F Aubin, L Malicenco, R Ramanah, D Riethmuller
Malignant melanoma represents 3% of cancers at the woman. The metastatic gynecological localization are rare and ovary is an exceptional site. Prognosis of metastatic ovary malignant melanoma is pejorative (5% 5 years survival). We report a case observed in a 65-year-old patient, who developed 2 melanomas of the left leg and presented a right ovarian tumor during a supervision tomodensitometric 7 years after diagnostic initial. The immunohistochemical assays after annexectomy confirmed the diagnostic of ovarian metastasis...
April 17, 2017: J Gynecol Obstet Hum Reprod
https://www.readbyqxmd.com/read/28425347/expression-and-clinicopathological-significance-of-mel-18-and-bmi-1-in-esophageal-squamous-cell-carcinoma
#9
Huaijun Ji, Ming Cao, Kunlun Ren, Ningbo Sun, Wei Wang, Qiang Zhu, Qi Zang, Zhongmin Jiang
The Polycomb group genes are a general class of regulators that are responsible for maintaining homeotic gene expression throughout cell division. Polycomb group expression plays an important role in oncogenesis of several types of human cancer. Melanoma nuclear protein 18 and B-cell-specific Moloney leukemia virus insert site 1 are key Polycomb group proteins. Studies have shown that melanoma nuclear protein 18 is a potential tumor suppression, and B-cell-specific Moloney leukemia virus insert site 1 is overexpressed in several human malignancies...
January 1, 2017: Technology in Cancer Research & Treatment
https://www.readbyqxmd.com/read/28421416/emergence-of-ctnnb1-mutation-at-acquired-resistance-to-kit-inhibitor-in-metastatic-melanoma
#10
J Cho, S Y Kim, Y J Kim, M H Sim, S T Kim, N K D Kim, K Kim, W Park, J H Kim, K-T Jang, J Lee
PURPOSE: The KIT inhibitor, imatinib, has shown promising efficacy in patients with KIT-mutated melanoma; however, acquisition of resistance to imatinib occurs rapidly in the majority of patients. The mechanisms of acquired resistance to imatinib in melanoma remain unclear. METHODS: We analyzed biopsy samples from paired baseline and post-treatment tumor lesions in one patient with KIT-mutated melanoma who had had an initial objective tumor regression in response to imatinib treatment followed by disease progression 8 months later...
April 18, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28417311/immune-checkpoint-inhibitors-for-brain-metastases
#11
REVIEW
Aaron C Tan, Amy B Heimberger, Alexander M Menzies, Nick Pavlakis, Mustafa Khasraw
PURPOSE OF REVIEW: Metastasis of cancer to the brain typically portends a poor prognosis and often results in significant morbidity, including from the side effects of treatment. More effective therapies for patients with brain metastases are needed. The current treatment paradigm uses multiple modalities, including surgery, radiation, and in some contexts, systemic chemotherapy and immunotherapy. Immune checkpoint inhibitors are increasingly being used to treat extracranial disease, and their effectiveness in the management of brain metastases needs to be understood...
June 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28414587/non-melanoma-skin-cancer-new-and-future-synthetic-drug-treatments
#12
Teresa Amaral, Claus Garbe
Non-melanoma skin cancers (NMSC) mainly comprise two different entities: basal cell carcinoma (BCC) and squamous cell carcinoma (SCC); beneath these two entities, Merkel cell carcinoma, adnexal tumors, dermatofibrosarcoma protuberans, angiosarcoma, and cutaneous lymphoma belong to NMSC. These rare skin tumors are not the topic of this review. BCC and SCC are the most common cancers diagnosed in humans. The preferred treatment is surgery, which in most cases is curative. Although a high recurrence rate is seen, these cancers rarely metastasize...
May 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28412591/baseline-%C3%AE-catenin-programmed-death-ligand-1-expression-and-tumour-infiltrating-lymphocytes-predict-response-and-poor-prognosis-in-braf-inhibitor-treated-melanoma-patients
#13
Daniela Massi, Emanuela Romano, Eliana Rulli, Barbara Merelli, Romina Nassini, Francesco De Logu, Ivan Bieche, Gianna Baroni, Laura Cattaneo, Gongda Xue, Mario Mandalà
BACKGROUND: The activation of oncogenic Wnt/β-catenin pathway in melanoma contributes to a lack of T-cell infiltration. Whether baseline β-catenin expression in the context of tumour-infiltrating lymphocytes (TILs) and programmed death ligand-1 (PD-L1) overexpression correlates with prognosis of metastatic melanoma patients (MMPs) treated with mitogen-activated protein kinase, MAPK inhibitor (MAPKi) monotherapy, however, has not been fully clarified. PATIENTS AND METHODS: Sixty-four pre-treatment formalin-fixed and paraffin embedded melanoma samples from MMP treated with a BRAF inhibitor (n = 39) or BRAF and MEK inhibitors (n = 25) were assessed for presence of β-catenin, PD-L1, cluster of differentiation (CD)8, CD103 and forkhead box protein P3 (FOXP3) expression by immunohistochemistry, and results were correlated with clinical outcome...
April 13, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28411392/clinical-prognostic-markers-in-stage-iiic-melanoma
#14
Max F Madu, Jaap H H Schopman, Danique M S Berger, Willem M C Klop, Katarzyna Jóźwiak, Michel W J M Wouters, Jos A van der Hage, Alexander C J van Akkooi
BACKGROUND: Although the EORTC 18071-trial has shown a clear survival benefit for adjuvant ipilimumab, accurately selecting patients for this toxic adjuvant therapy is important. We aimed to identify prognostic factors for death and disease recurrence in AJCC stage IIIC melanoma patients. PATIENTS AND METHODS: Retrospective analysis of patients who underwent lymph node dissection (LND) for stage IIIC melanoma in our institution between 2000 and 2016. Baseline characteristics, melanoma-specific survival (MSS), and disease-free survival (DFS) were assessed, and prognostic factors for recurrence and survival were analyzed using uni- and multivariable analysis...
April 15, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28409552/long-noncoding-rna-pvt1-promotes-melanoma-progression-via-endogenous-sponging-mir-26b
#15
Bao-Juan Wang, Hong-Wei Ding, Guo-An Ma
Melanoma is an extremely aggressive and high mortality skin malignant tumor, and various long noncoding RNAs (lncRNAs)have been reported to be associated with the oncogenesis of melanoma. The purpose of this study is to investigate the potential roles of lncRNA PVT1 in melanoma progression and to explore the possible mechanisms. A total of 35 patients who were diagnosed as malignant melanoma were enrolled in this study. Expression of PVT1 was significantly up-regulated in melanoma tissue and associated with poor prognosis...
April 12, 2017: Oncology Research
https://www.readbyqxmd.com/read/28408492/cd81-as-a-tumor-target
#16
REVIEW
Felipe Vences-Catalán, Caroline Duault, Chiung-Chi Kuo, Ranjani Rajapaksa, Ronald Levy, Shoshana Levy
CD81 participates in a variety of important cellular processes such as membrane organization, protein trafficking, cellular fusion and cell-cell interactions. In the immune system, CD81 regulates immune synapse, receptor clustering and signaling; it also mediates adaptive and innate immune suppression. CD81 is a gateway in hepatocytes for pathogens such as hepatitis C virus and Plasmodium; it also confers susceptibility to Listeria infection. These diverse biological roles are due to the tendency of CD81 to associate with other tetraspanins and with cell-specific partner proteins, which provide the cells with a signaling platform...
April 15, 2017: Biochemical Society Transactions
https://www.readbyqxmd.com/read/28404968/loss-of-nuclear-bap1-expression-is-associated-with-poor-prognosis-in-oral-mucosal-melanoma
#17
Hao Song, Lizhen Wang, Jiong Lyu, Yunteng Wu, Wei Guo, Guoxin Ren
Oral mucosal melanoma (OMM) is an aggressive neoplasm with an extremely poor prognosis. BAP1 is a tumor suppressor that has been associated with the outcome of melanomas and other malignancies. In this study, we investigated the genetic alterations in BAP1 and the prognostic potential of BAP1 protein expression in oral mucosal melanoma. DNA sequence analysis of BAP1 from 12 OMM patient samples revealed missense mutations in the tissues from four patients. Based on immunohistochemical staining, loss of nuclear BAP1 expression was associated with poor overall survival (P < 0...
March 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28403786/immune-checkpoint-inhibitors-and-cardiac-toxicity-an-emerging-issue
#18
Gilda Varricchi, Giancarlo Marone, Valentina Mercurio, Maria Rosaria Galdiero, Domenico Bonaduce, Carlo G Tocchetti
Although survival of patients with different types of cancer has improved, cardiotoxicity induced by anti-neoplastic drugs remains a critical issue. Cardiac dysfunction after treatment with anthracyclines has historically been a major problem. However, also targeted therapies and biological molecules can induce reversible and irreversible cardiac dysfunction. Cancer immunotherapies over the last years have revolutionized the clinical management of a wide spectrum of solid and hematopoietic malignancies previously endowed with poor prognosis...
April 7, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28403068/malignant-melanoma-in-african-americans-a-population-based-clinical-outcomes-study-involving-1106-african-american-patients-from-the-surveillance-epidemiology-and-end-result-seer-database-1988-2011
#19
Krishnaraj Mahendraraj, Komal Sidhu, Christine S M Lau, Georgia J McRoy, Ronald S Chamberlain, Franz O Smith
Malignant melanoma accounts for 75% of all skin cancer deaths and is potentially curable if identified early. Although melanoma is rare in African-Americans (AA), it is associated with a worse prognosis than in Caucasians. This study examines the demographic, pathologic, and clinical factors impacting AA melanoma outcomes.Data for 1106 AA and 212,721 Caucasian cutaneous melanoma patients were abstracted from the Surveillance, Epidemiology, and End Result (SEER) database (1988-2011). Data were grouped on the basis of histological subtypes: "Superficial Spreading" (SS), "Nodular" (NM), "Lentigo Maligna" (LM), "Acral Lentiginous" (AL), and "Not otherwise specified" (NOS)...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28396509/clinical-features-of-acquired-resistance-to-anti-pd-1-therapy-in-advanced-melanoma
#20
Daniel Y Wang, Zeynep Eroglu, Alpaslan Ozgun, Paul D Leger, Shilin Zhao, Fei Ye, Jason J Luke, Richard W Joseph, Rizwan Haq, Patrick A Ott, F Stephen Hodi, Jeffrey A Sosman, Douglas B Johnson, Elizabeth I Buchbinder
Anti-PD-1 therapy has improved clinical outcomes in advanced melanoma, but most patients experience intrinsic resistance. Responding patients can develop acquired resistance to anti-PD-1. We retrospectively reviewed 488 patients treated with anti-PD-1 from three academic centers and identified 36 patients with acquired resistance, defined as disease progression following objective response. The incidence, timing, disease sites, post-progression survival (PPS), and outcomes were evaluated descriptively. The acquired resistance cohort consisted of 67% with more than 1 feature of poor prognosis (stage M1c, elevated LDH, or brain metastasis), and 67% had previously received ipilimumab...
April 10, 2017: Cancer Immunology Research
keyword
keyword
87273
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"